Physician profile
Syed Rizvi
NPI 1467807354
$1,128.33
in general payments reported to CMS, 2019-2025
14 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $109 · 2022: $137 · 2023: $312 · 2024: $184 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $882.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $221.09 | 2023-2025 | |
| Mirum Pharmaceuticals, INC. | $185.07 | 2022-2025 | Livmarli |
| Regeneron Healthcare Solutions, INC. | $173.46 | 2022-2024 | Dupixent |
| Abbvie INC. | $131.10 | 2020-2022 | |
| Alcresta Therapeutics, INC. | $128.73 | 2023-2024 | Relizorb |
| Takeda Pharmaceuticals U.S.A., INC. | $97.30 | 2022-2025 | Gattex |
| Neuraxis, INC. | $54.24 | 2025 | |
| Albireo Pharma, INC. | $36.89 | 2022-2023 | Bylvay |
| Dentsply Ih Ab | $28.65 | 2025 | Navina Rectal Catheter Set Regular |
| Acadia Pharmaceuticals INC | $21.42 | 2025 | Daybue |
| Glaxosmithkline, LLC. | $14.92 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $13.46 | 2025 | Iqirvo |
| Pharming Healthcare, INC. | $13.15 | 2022 | |
| Travere Therapeutics, INC. | $8.85 | 2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.